载有冬凌草甲素的纳米结构脂质载体的体内研究。
In vivo studies on the oridonin-loaded nanostructured lipid carriers.
机构信息
Department of Pharmaceutics, College of Pharmacy, Shandong University, Jinan, PR China.
出版信息
Drug Deliv. 2012 Aug;19(6):286-91. doi: 10.3109/10717544.2012.704096. Epub 2012 Aug 28.
Oridonin (ORI)-loaded Nanostructured lipid carriers (NLC) were prepared by emulsion-evaporation and low temperature-solidification technique, and evaluated for morphological observation, particle size, zeta potential and in vitro drug release. Next, the characteristics of biodistribution and pharmacokinetics in vivo were examined. The average particle size of resultant NLC was 245.2 nm and the zeta potential was found to be -38.77 mV. The in vivo characteristics of ORI-loaded NLC were studied after intravenous administration using Kunming strain mice as experimental animals. An ORI control solution was studied parallelly. In tested organs, the distribution of ORI-loaded NLC to liver was higher than that of free drug. ORI-loaded NLC showed higher AUC (area under tissue concentration-time curve) values and circulated in the blood stream for a longer time compared with ORI solution. These results support the potential applications of NLC for the delivery of ORI.
冬凌草甲素(ORI)负载的纳米结构脂质载体(NLC)通过乳化蒸发和低温固化技术制备,并对其形态观察、粒径、Zeta 电位和体外药物释放进行评价。接下来,考察了体内的分布特征和药代动力学。所得 NLC 的平均粒径为 245.2nm,Zeta 电位为-38.77mV。以昆明种小鼠为实验动物,静脉给药后研究 ORI 负载 NLC 的体内特征。平行研究了 ORI 对照溶液。在测试的器官中,ORI 负载 NLC 向肝脏的分布高于游离药物。与 ORI 溶液相比,ORI 负载 NLC 表现出更高的 AUC(组织浓度-时间曲线下面积)值,并在血液中循环更长时间。这些结果支持 NLC 作为 ORI 传递的潜在应用。